Metabolic & Weight Loss · Source-reviewed dossier
Adipotide
Source-Reviewed Research Dossier
Adipotide is studied for a strategy that targets blood vessels supporting fat tissue. It links a targeting part to a cell-death signal. A small experiment in obese rhesus monkeys reported lower body weight, less white fat and improved insulin-resistance measures. The same report described reversible kidney-tubule changes, so the safety findings matter alongside weight loss. Later mouse work compared delivery formats. These are animal findings, not established benefits or safety in people, and they do not validate NHD research material.
Compound overview
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.
Product identity
- Product type
- Peptide research compound
- Catalog family
- Adipotide
- Research category
- Metabolic & Weight Loss
- Catalog CAS RN
- 859216-15-2
- Catalog sequence
- Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Cys-Gly-Gly-D(Lys-Leu-Ala-Lys-Leu-Ala-Lys)2
- Evidence status
- Non-human primate and preclinical evidence; no approved human use
- Intended use
- Research, development and manufacturing use only
Literature reference parameters
- Compound or material class
- Prohibitin-targeting peptidomimeticCatalog-family identity
- Evidence scope
- Non-human primate and preclinical evidence; no approved human useDo not generalize beyond the cited model
- Source review
- Primary or authoritative records linked belowChecked 2026-09-01
Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.
How Adipotide is studied
A target-to-pathway view grounded in the linked research records.
Reported research findings
What published studies report about Adipotide
Reported outcomes are paired with their experimental model and evidence boundary.
Obese-monkey study reported weight and insulin-resistance changes
The published study reported loss of white adipose tissue, body-weight reduction and improved insulin-resistance measures in obese rhesus monkeys.
This was a small non-human-primate experiment with a defined research construct; it was not a human treatment trial.
Read the primary studyTargeted therapeutic formats were compared in obesity models
A later preclinical study compared nanoparticle-targeted therapeutics and peptide bioconjugates as adipose-vascular targeting approaches.
The experiment informs delivery strategy rather than human effectiveness or catalog-lot quality.
Read the primary studyCatalog options
Variant specifications
Pack-level catalog data; lot-level controls remain document-specific.
Specification & documents for AP2
Product specification
Single-component peptide · 2 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Lot documentation
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Specification & documents for AP5
Product specification
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Lot documentation
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Specification & documents for AP10
Product specification
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Lot documentation
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Quality documentation
A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.
Analytical interpretation
Interpret the documents, not just the headline number.
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Research context
Published studies and regulatory records, not customer testimonials or usage guidance.
Obese-monkey study reported weight and insulin-resistance changes
This was a small non-human-primate experiment with a defined research construct; it was not a human treatment trial.
View primary recordTargeted therapeutic formats were compared in obesity models
The experiment informs delivery strategy rather than human effectiveness or catalog-lot quality.
View primary recordCurated references
Third-party publications selected for direct relevance.
-
01
Non-human primate
A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys
Barnhart KF, et al. Science Translational Medicine. 2011. PMID 22072637.
-
02
Preclinical comparison
Comparative study of nanoparticle-targeted therapeutics and bioconjugates
Daquinag AC, et al. Molecular Pharmaceutics. 2013. PMID 23871959.
Adipotide questions
Concise answers for researchers comparing identity, evidence and catalog variants.
What effects are studied for Adipotide?
In obese monkeys, a defined research version was reported to cause cell death in fat blood vessels and produce weight loss, reduced white fat on imaging, and improved insulin-resistance measures. Reversible kidney tubule changes were also seen at tested doses. A separate mouse study compared delivery formats. These are early non-human findings, not demonstrated human outcomes.
How should the Adipotide research findings be understood?
A later mouse comparison tested a nanoparticle carrying the same cell-death peptide against a linked peptide version. The nanoparticle was reported to lower body weight and leptin, reduce fat in liver and muscle, raise adiponectin, and show no detectable liver toxicity in that model. This informs delivery strategy, not human effectiveness or catalog quality.
What evidence is available for Adipotide?
One directly relevant non-human-primate study and additional preclinical delivery research are available.
Does the cited research validate this catalog material?
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
Which quality documents can be requested?
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
How should Adipotide be stored?
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge tools
Continue with structured evidence
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Ready to request a quote?
Selected: AP2 · 2 mg × 10 vials